Skip to main content
Fig. 4 | Virology Journal

Fig. 4

From: Development of a neutralization monoclonal antibody with a broad neutralizing effect against SARS-CoV-2 variants

Fig. 4

Therapeutic efficacy of SKAI-DS84 in B.1.1.529-infected K18-hACE2 expressing mice. After infecting K18-hACE2 mice with 105 PFU of B.1.1.529 virus, 50 mg/kg SKAI-DS84 was intravenously injected within 4 h. All experiments were analyzed 2 and 7 days after viral infection. a Monitoring the survival and activity of infected mice. b Measurement of viral copies using RT-qPCR and TCID50. Histopathological analysis of SKAI-DS84-treated or untreated mice infected with B.1.1.529: c lung, d spleen, e duodenum. *P < 0.05, **P < 0.01, significantly different from control. Scale bar = 100 μm

Back to article page

Virology Journal

ISSN: 1743-422X